Stemline Therapeutics (NASDAQ:STML) is a biopharmaceutical company that is developing cancer therapies targeting cancer stem cells. Stemline presented some exciting results for its lead program SL-104 this weekend at the American Society of Clinical Oncology (OTC:ASCO) meeting in Chicago, validating the company as a strong contender in the cancer stem cell treatment space. The data for lead candidate SL-401 included a response for 5 out of 6 blastic plasmacyoid dendritic cell neoplasm (BPDCN) patients and an increase in overall survival for refractory/relapsed acute myeloid leukemia (AML) patients. SL-401 is a recombinant protein consisting of human interleukin-3 (IL-3), designed to find IL-3 receptors on cancer cells and cancer stem cells, bound to a toxic payload.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|